公开(公告)号：JP2013209377A

公开(公告)日：2013-10-10

申请号：JP2013086296

申请日：2013-04-17

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： BROWMAN KAITLIN E ,  ROHDE JEFFREY ,  JACOBSON PEER B ,  BRUNE MICHAEL E ,  RUETER LYNNE E ,  WANG JIAHONG ,  LINK JAMES T ,  ROBERT S BITNER ,  CHEN YIXIAN ,  DINGES JURGEN ,  DRESCHER KARLA ,  JAE HWAN-SOO ,  KURUKULASURIYA RAVI ,  MADAR DAVID J ,  PATEL JYOTI ,  PLIUSHCHEV MARINA ,  SHUAI QI ,  SORENSEN BRYAN ,  WICKE KARSTEN ,  WINN MARTIN ,  WODKA DARIUSZ ,  YEH VINCE ,  YONG HONG

IPC: A61K45/00 ,  A61K31/16 ,  A61P25/00 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P43/00

CPC classification number: C07D403/12 ,  A61K31/44 ,  A61K31/495 ,  C07D207/267 ,  C07D401/12 ,  C07D401/14

Abstract: PROBLEM TO BE SOLVED: To provide a therapeutic agent for a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, and schizophrenia.SOLUTION: A pharmaceutical composition includes an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase type 1 enzyme activity represented by formula.

Abstract translation: 要解决的问题：为患有与衰老和神经变性相关的糖尿病中枢神经系统紊乱和缺陷的患者提供治疗剂，其包括注意力缺陷障碍，注意力缺陷多动障碍（ADHD），阿尔茨海默病 （AD），轻度认知障碍，老年性痴呆，艾滋病痴呆，神经变性和精神分裂症。解决方案：药物组合物包括有效量的由式表示的11-＆bgr-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。

公开(公告)号：JP2009046464A

公开(公告)日：2009-03-05

申请号：JP2007241117

申请日：2007-09-18

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： BROWMAN KAITLIN E ,  ROHDE JEFFREY ,  JACOBSON PEER B ,  BRUNE MICHAEL E ,  RUETER LYNNE E ,  WANG JIAHONG ,  LINK JAMES T ,  ROBERT S BITNER ,  CHEN YIXIAN ,  DINGES JURGEN ,  DRESCHER KARLA ,  JAE HWAN-SOO ,  KURUKULASURIYA RAVI ,  MADAR DAVID J ,  PATEL JYOTI ,  PLIUSHCHEV MARINA ,  SHUAI QI ,  SORENSEN BRYAN ,  WICKE KARSTEN ,  WINN MARTIN ,  WODKA DARIUSZ ,  YEH VINCE ,  YONG HONG

IPC: A61K31/165 ,  A61K31/496 ,  A61P25/00 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P43/00 ,  C07D213/74

CPC classification number: C07D403/12 ,  A61K31/44 ,  A61K31/495 ,  C07D207/267 ,  C07D401/12 ,  C07D401/14

Abstract: PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for treating patients with diabetes-, aging- and neurodegeneration-related central-nervous-system disorders and deletions including ordinary attention-deficit disorders, attention-deficit hyperactivity disorders (ADHD), Alzheimer's disease (AD), mild cognitive damage, senile dementia, AIDS dementia, neurodegeneration and schizophrenia. SOLUTION: The pharmaceutical composition for treating glucocorticoid-related central-nervous-system disorders contains a selective inhibitor for 11-β-hydroxysteroid dehydrogenase 1-type enzyme activity. COPYRIGHT: (C)2009,JPO&INPIT

Abstract translation: 待解决的问题：提供一种用于治疗患有糖尿病，老化和神经变性相关的中枢神经系统疾病和缺失的药物组合物，包括普通注意力缺陷障碍，注意力缺陷多动障碍（ADHD） 阿尔茨海默病（AD），轻度认知损伤，老年痴呆，艾滋病痴呆，神经变性和精神分裂症。 解决方案：用于治疗糖皮质激素相关中枢神经系统疾病的药物组合物含有11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。 版权所有（C）2009，JPO＆INPIT

公开(公告)号：WO2009026422A2

公开(公告)日：2009-02-26

申请号：PCT/US2008073830

申请日：2008-08-21

Applicant: ABBOTT LAB ,  BITNER R SCOTT ,  BROWMAN KAITLIN E ,  BRUNE MICHAEL E ,  CHEN YIXIAN ,  DINGES JURGEN ,  DRESCHER KARLA ,  JACOBSON PEER ,  JAE HWAN-SOO ,  KURUKULASURIYA RAVI ,  LINK JAMES T ,  MADAR DAVID J ,  PATEL JYOTI R ,  PLIUSHCHEV MARINA A ,  ROHDE JEFFREY J ,  RUETER LYNNE E ,  SHUAI QI ,  SORENSEN BRYAN K ,  WANG JIAHONG ,  WICKE KARSTEN M ,  WINN MARTIN ,  WODKA DARIUSZ ,  YEH VINCE ,  YONG HONG

Inventor： BITNER R SCOTT ,  BROWMAN KAITLIN E ,  BRUNE MICHAEL E ,  CHEN YIXIAN ,  DINGES JURGEN ,  DRESCHER KARLA ,  JACOBSON PEER ,  JAE HWAN-SOO ,  KURUKULASURIYA RAVI ,  LINK JAMES T ,  MADAR DAVID J ,  PATEL JYOTI R ,  PLIUSHCHEV MARINA A ,  ROHDE JEFFREY J ,  RUETER LYNNE E ,  SHUAI QI ,  SORENSEN BRYAN K ,  WANG JIAHONG ,  WICKE KARSTEN M ,  WINN MARTIN ,  WODKA DARIUSZ ,  YEH VINCE ,  YONG HONG

IPC: A61K31/495 ,  A61K31/44

CPC classification number: C07D403/12 ,  A61K31/44 ,  A61K31/495 ,  C07D207/267 ,  C07D401/12 ,  C07D401/14

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-ß-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Abstract translation: 用于治疗患有与糖尿病相关的中枢神经系统与衰老和神经变性有关的障碍和缺陷的患者的方法，其包括一般的注意力缺陷障碍，注意力缺陷多动障碍（ADHD），阿尔茨海默病（AD），轻度认知障碍 老年痴呆症，艾滋病痴呆症，神经变性，抑郁症和精神分裂症的方法，包括向需要这种治疗的患者施用有效量的11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。

公开(公告)号：WO0218031A2

公开(公告)日：2002-03-07

申请号：PCT/US0125571

申请日：2001-08-15

Applicant: ABBOTT LAB

Inventor： WODKA DARIUSZ ,  GENTLES ROBERT G

IPC: B01D35/30 ,  B01L3/00 ,  B01L3/14 ,  B01D37/00

CPC classification number: B01L3/50255 ,  B01D35/306 ,  B01L3/50825

Abstract: A filtering device comprising a filtering element that can be attached to an adapter. The filtering element comprises a mesh surrounding a cavity. The mesh of the filtering element is constructed to have sufficient porosity so that hydrostatic and mechanical pressures force the liquid components of a suspension into the cavity of the filtering element from where they can be aspirated and collected. Preferably, at least one semi-rigid rib supports the mesh. This invention also involves a method for using the filtering device in a variety of applications. These applications include, but are not limited to, sampling of suspensions, filtration of particulate materials from suspensions, and purification or isolation of chemical or biological components contained within the a suspension.

Abstract translation: 一种过滤装置，包括可附接到适配器的过滤元件。 过滤元件包括围绕空腔的网。 过滤元件的网格被构造成具有足够的孔隙度，使得静水压力和机械压力迫使悬浮液的液体组分进入过滤元件的空腔，从那里它们可以被抽吸和收集。 优选地，至少一个半刚性肋支撑网。 本发明还涉及在各种应用中使用过滤装置的方法。 这些应用包括但不限于悬浮液的取样，悬浮液中的颗粒物质的过滤，以及纯化或分离悬浮液中所含的化学或生物成分。

公开(公告)号：AU2011202889A1

公开(公告)日：2011-07-07

申请号：AU2011202889

申请日：2011-06-16

Applicant: ABBOTT LAB

Inventor： WODKA DARIUSZ ,  LINK JAMES T ,  SHUAI QI ,  PATEL JYOTI R ,  PLIUSHCHEV MARINA A ,  ROHDE JEFFREY J

IPC: C07D207/02 ,  C07C237/04 ,  C07C237/24 ,  C07D209/08 ,  C07D213/06 ,  C07D213/24 ,  C07D213/72 ,  C07D213/74 ,  C07D213/85 ,  C07D223/16 ,  C07D253/06 ,  C07D257/04 ,  C07D277/64 ,  C07D295/15 ,  C07D295/185 ,  C07D471/08 ,  C07D491/04

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta hydroxysteroid dehydrogenase Type I enzyme. The present invention further relates to the use of inhibitors of 11 -beta-hydroxysteroid dehydrogenase Type I enzyme for the io treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

公开(公告)号：BR0012502A

公开(公告)日：2003-06-24

申请号：BR0012502

申请日：2000-12-15

Applicant: ABBOTT LAB

Inventor： BASHA FATIMA Z ,  HINMAN MIRA M ,  KOPECKA HANA A ,  SEARLE XENIA B ,  SOWIN THOMAS J ,  WODKA DARIUSZ ,  SUROWY CAROL ,  FALTYNEK CONNIE R

IPC: C07D295/08 ,  A61K31/17 ,  A61K31/35 ,  A61K31/357 ,  A61K31/397 ,  A61K31/40 ,  A61K31/402 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/453 ,  A61K31/454 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/54 ,  A61K31/541 ,  A61K31/55 ,  A61P11/06 ,  A61P43/00 ,  C07C275/32 ,  C07D207/06 ,  C07D207/12 ,  C07D211/46 ,  C07D235/26 ,  C07D239/10 ,  C07D241/08 ,  C07D265/30 ,  C07D295/096 ,  C07D295/10 ,  C07D295/18 ,  C07D295/20 ,  C07D295/205 ,  C07D295/215 ,  C07D309/04 ,  C07D309/08 ,  C07D309/10 ,  C07D309/12 ,  C07D401/12 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D413/12 ,  C07D417/12 ,  C07D491/113 ,  A61K31/41

公开(公告)号：NZ551508A

公开(公告)日：2010-10-29

申请号：NZ55150805

申请日：2005-04-29

Applicant: ABBOTT LAB

Inventor： LINK JAMES T ,  PLIUSHCHEV MARINA A ,  ROHDE JEFFREY J ,  WODKA DARIUSZ ,  PATEL JYOTI R ,  SHUAI QI

IPC: C07D207/02 ,  C07C237/04 ,  C07C237/24 ,  C07D209/08 ,  C07D213/06 ,  C07D213/24 ,  C07D213/72 ,  C07D213/74 ,  C07D213/85 ,  C07D223/16 ,  C07D253/06 ,  C07D257/04 ,  C07D277/64 ,  C07D295/15 ,  C07D295/185 ,  C07D471/08 ,  C07D491/04

Abstract: Disclosed is a compound according to formula (I) wherein A1 is alkyl-NH-alkyl, alkylcarbonyl, alkylsulfonyl, cycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, arylcarbonyl, arylsulfonyl, heterocyclecarbonyl, heterocyclesulfonyl, arylalkyl, aryloxyalkyl, carboxyalkyl, carboxycycloalkyl, haloalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, -NR7-[C(R8R9)]n-C(O)-R10, -O-[C(R11R12)]p-C(O)-R13, -N(R15R16), -CO2R17, -C(O)-N(R18R19), -CR20R21)-OR22, or -C(R23R24)-N(R25R26); and wherein the rest of the substituents are disclosed within the specification. Also disclosed is the use of a compound of formula (I) in the manufacture of a medicament for treating a disorder associated with the inhibition of 11-beta-hydroxysteroiddehydrogenase type 1 enzyme selected from Cushing's syndrome, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, hypertension, atherosclerosis, glaucoma, and osteoporosis.

公开(公告)号：CA2568241A1

公开(公告)日：2005-11-17

申请号：CA2568241

申请日：2005-04-29

Applicant: ABBOTT LAB

Inventor： ROHDE JEFFREY J ,  WODKA DARIUSZ ,  SHUAI QI ,  PATEL JYOTI R ,  LINK JAMES T ,  PLIUSHCHEV MARINA A

IPC: C07D213/06 ,  A61K31/44 ,  A61K31/445 ,  C07C237/04 ,  C07C237/24 ,  C07D207/02 ,  C07D209/08 ,  C07D213/24 ,  C07D213/72 ,  C07D213/74 ,  C07D213/85 ,  C07D223/16 ,  C07D253/06 ,  C07D257/04 ,  C07D277/64 ,  C07D295/15 ,  C07D295/185 ,  C07D471/08 ,  C07D491/04

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

公开(公告)号：CA2488635C

公开(公告)日：2012-10-23

申请号：CA2488635

申请日：2003-06-11

Applicant: ABBOTT LAB

Inventor： BLACKBURN CHRISTOPHER ,  LAI SU-JEN ,  CHE JENNIFER L ,  MAGUIRE MARTIN ,  PATANE MICHAEL A ,  LAMARCHE MATTHEW J ,  CULLIS COURTNEY A ,  BROWN JAMES ,  VASUDEVAN ANIL ,  FREEMAN JENNIFER C ,  MULHERN MATHEW M ,  LYNCH JOHN K ,  GAO JU ,  WODKA DARIUSZ ,  SOUERS ANDREW J ,  IYENGAR RAJESH ,  VERZAL MARY KATHERINE ,  KYM PHILIP R

IPC: C07D403/14 ,  C07D405/14 ,  A61K31/4468 ,  A61K31/453 ,  A61K31/4535 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/517 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P5/00 ,  A61P15/00 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P43/00 ,  C07D401/14 ,  C07D405/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D451/04

Abstract: This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1). The compounds are represented by formula (I): where m is zero or one, n is zero to two, Y is oxygen or -N (R9)-, R1, R2, R3, R4, R5, R9, and Ring A are defined in the specification. Coumarin and quinolone compounds where R1 and R2 together form a fused benzo ring are preferred. The invention also provides compounds of formula (VI) where the coumarin moiety is replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related disorders, particularly overweight conditions including obesity.

公开(公告)号：AU2005241073A1

公开(公告)日：2005-11-17

申请号：AU2005241073

申请日：2005-04-29

Applicant: ABBOTT LAB

Inventor： ROHDE JEFFREY J ,  PATEL JYOTI R ,  PLIUSHCHEV MARINA A ,  WODKA DARIUSZ ,  LINK JAMES T ,  SHUAI QI

IPC: C07D207/02 ,  C07C237/04 ,  C07C237/24 ,  C07D209/08 ,  C07D213/06 ,  C07D213/24 ,  C07D213/72 ,  C07D213/74 ,  C07D213/85 ,  C07D223/16 ,  C07D253/06 ,  C07D257/04 ,  C07D277/64 ,  C07D295/15 ,  C07D295/185 ,  C07D471/08 ,  C07D491/04

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.